Letter
Cannabidiol in dystonic movement disorders

https://doi.org/10.1016/0165-1781(86)90117-4Get rights and content

Cited by (26)

  • Cannabinoids in the treatment of movement disorders: A systematic review of case series and clinical trials

    2016, Basal Ganglia
    Citation Excerpt :

    There have not been any neuropathologic or imaging studies of cannabinoid receptor levels in individuals with dystonia. The anti-dystonic effects reported in an animal model and several case reports in individuals with focal or generalized dystonia suggest that cannabinoid treatment may be beneficial in individuals with dystonia [62–69]. Only three clinical studies have looked at cannabinoid agonist treatment in dystonia to date.

  • Phytocannabinoids as novel therapeutic agents in CNS disorders

    2012, Pharmacology and Therapeutics
    Citation Excerpt :

    However, daily treatment with Δ9-THC (10 mg/kg over 8 weeks) reportedly had no effect on motor deterioration in a mouse transgenic model of HD (Dowie et al., 2010). A small clinical trial following daily CBD (300–600 mg) treatment demonstrated an improvement in HD symptoms in 1 of 4 participants (Sandyk et al., 1986); however, a double-blind randomised placebo-controlled crossover trial in 15 HD patients showed no significant effect of CBD (10 mg/kg/day, 6 weeks) on chorea severity (Consroe et al., 1991). More recently, a randomised, double-blind crossover placebo-controlled trial with 37 patients investigating the effects of the synthetic Δ9-THC analogue nabilone (1–2 mg) showed no effect on the primary outcome (the Unified Huntington's Disease Rating Scale), but some evidence of improvement in chorea and neuropsychiatric outcomes (Curtis et al., 2009).

  • Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats

    2004, Neuropharmacology
    Citation Excerpt :

    Some cannabis extracts are also rich in cannabidiol (CBD), which is chemically similar to Δ9-THC but devoid of any psychoactivity (Pertwee, 1988,2004). CBD is anxiolytic (Musty, 1984; Guimarães et al., 1990; Zuardi et al., 1982), anticonvulsant (Karler and Turkanis, 1981; Wallace et al., 2001), neuroprotective (Hampson et al., 1998), anti-inflammatory (Sofia et al., 1973; Evans et al., 1987), affects growth and proliferation of cancer cells (Jacobsson et al., 2000) and improves motor function in dystonic patients (Sandyk et al., 1986). These data suggest that CBD has some effects in common with Δ9-THC, but detailed behavioral testing of synthetic CBD- or CBD-rich cannabis extracts on memory and learning has not been reported.

  • Drugs of abuse

    1988, Side Effects of Drugs Annual
View all citing articles on Scopus
View full text